Abstract
This study evaluates the incidence and clinical characteristics of renal cell carcinoma (RCC) in patients undergoing dialysis in Japan. By analyzing data from a 2004 questionnaire and reviewing 12 biennial surveys conducted since 1982, the research tracks long-term trends across 2,873 cases. The findings reveal that while the total number of diagnosed cases has risen significantly over two decades, the average tumor size at discovery has decreased, and metastasis rates have declined. These trends suggest that widespread screening protocols are successfully identifying malignancies at earlier, more manageable stages.
Introduction
Patients with end-stage renal disease (ESRD) on long-term dialysis face a significantly elevated risk of developing renal cell carcinoma (RCC) compared to the general population. This increased susceptibility is closely linked to Acquired Renal Cystic Disease (ARCD), a condition where the non-functioning kidneys develop multiple cysts over time. Understanding the evolving landscape of RCC in this high-risk group is critical for refining screening and treatment strategies.
Methods and Datasets
The study utilized a series of 12 biennial national surveys sent to dialysis facilities and urology departments across Japan from 1982 to 2004.
- The 2004 Survey: Collected data on 534 new cases (420 males, 112 females) diagnosed between March 2002 and February 2004. It included new metrics such as the timing of metastasis discovery and specific renal replacement therapy modalities.
- Longitudinal Review: Aggregated results from all 12 surveys to analyze trends in a total cohort of 2,873 cases.
- Response Rate: The 2004 survey achieved a 62.7% response rate from 3,345 questionnaires sent.
Trends in Case Volume and Demographics
Over the 22-year study period, the number of reported RCC cases in the dialysis population has grown steadily. This growth reflects both the increasing number of patients on long-term dialysis and improved diagnostic vigilance.
The data shows a consistent male predominance, with a male-to-female ratio of approximately 4:1. The average age at diagnosis was 55.5 ± 11.5 years, and the average duration of dialysis prior to diagnosis was 126.9 ± 84.9 months.
Key Insights
The "Screening Effect"
A primary finding of the longitudinal analysis is the reduction in tumor size at the time of discovery. The average diameter decreased from 4.25 cm in the early 1980s to 3.53 cm in 2004. This shift is attributed to the adoption of routine screening (ultrasound and CT), which allows for the detection of smaller, asymptomatic tumors. Consequently, the metastasis rate at diagnosis has also trended downward, from a historical average of 15.4% to 13.9% in the most recent cohort.
The ARCD Connection
The study confirms a powerful association between cystic transformation and malignancy. Approximately 81.3% of the RCC cases were complicated by ARCD, reinforcing the need for regular monitoring of the native kidneys in long-term dialysis patients.
Comparative Risk
Dialysis patients exhibit a dramatically higher incidence of RCC than the general public. The Standardized Incidence Ratio (SIR) indicates that males on dialysis are 14.3 times more likely, and females 17.1 times more likely, to develop kidney cancer than their non-dialysis counterparts.
Conclusion
Renal cell carcinoma remains a major long-term complication of dialysis. However, the 22-year data from Japan provides a positive outlook: tumors are being caught earlier and smaller. As dialysis patients live longer, the importance of persistent, high-quality screening of the native kidneys cannot be overstated. Future research should continue to monitor these trends to determine if earlier detection translates into improved long-term survival rates for this vulnerable population.
Reference: Ishikawa, I. (2005). Present status of renal cell carcinoma in dialysis patients: A questionnaire study in 2004 and review of past questionnaires since 1982. The Japanese Journal of Dialysis Therapy, 38(11), 1689-1700.
Summary updated